CD93 and acute myeloid leukemia: In this model, endothelial cells were protected and not damaged from CD93 CAR T. CD93 represents a potentially effective target for CAR-T in AML treatment; however, the cross-reactivity against endothelial cells is a challenging problem to overcome [101].